Albumin Is Fastest Growing Segment Fueling The Growth Of Blood Plasma Derivatives Market

 

The global Blood Plasma Derivatives Market is estimated to be valued at US$ 44.33 Bn in 2023 and is expected to exhibit a CAGR of 9.3% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market Overview:
Blood plasma derivatives are proteins made from blood plasma, which is the liquid component of blood that remains after removing red and white blood cells. The key derivatives include albumin, immunoglobulin, coagulation factors, hyperimmune globulins, and other specialty proteins. These proteins play a crucial role in maintaining homeostasis, immunity, and coagulation.

Market key trends:
The demand for albumin is rising significantly driven by its wide applications in treating various respiratory diseases, shock or trauma, burns, liver diseases, and other chronic illnesses. Albumin helps maintain adequate blood volume and pressure for circulatory functions. It is commonly used during major surgeries to replace lost fluids and nutrients. The growing prevalence of chronic and lifestyle diseases along with aging population is expected to propel the demand for albumin and fuel the growth of the blood plasma derivatives market over the forecast period.

Segment Analysis

The global blood plasma derivatives market is segmented into albumin, immunoglobulins, coagulation factor concentrates, and protease inhibitors. Among these, the immunoglobulins segment accounts for the largest market share of over 35% in 2023. Immunoglobulins are becoming the core treatment for various primary immunodeficiency disorders and are dominating the market due to their widespread applications in autoimmune disorders and infections.

Key Takeaways

The Global Blood Plasma Derivatives Market Size is expected to witness high growth, exhibiting CAGR of 9.3% over the forecast period, due to increasing prevalence of immunodeficiency and autoimmune disorders.

Regional Analysis

North America dominates the global blood plasma derivatives market with over 45% share in 2023 and is expected to retain its position over the forecast period. This is attributed to the high adoption of immunoglobulins and albumin for various applications in the region. Asia Pacific is expected to witness the fastest growth over 2023-2030 owing to increasing healthcare infrastructure coupled with growing medical tourism in countries such as India, China, and Japan.

Key Players

Key players operating in the blood plasma derivatives market are Shire Plc., CSL Limited, Octapharma AG, LFB S.A., Biotest AG, Grifols, S.A., SK Plasma Co., Ltd., Baxter International Inc., Green Cross Corporation, and Fusion Health Care Pvt. Ltd., among others. Shire Plc. is expected to lead the market over 2023-2030, supported by its diverse immunoglobulin portfolio and wide geographic footprint.

Read More: https://www.ukwebwire.com/blood-plasma-derivatives-market-size-share-and-growth-forecast-2023-2030/